• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • Skip to investors navigation
Scholar Rock

Scholar Rock

Discovery and Development of Innovative Medicines

  • Careers
  • Newsroom
  • Contact Us
  • Patients & Families
    • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access

    Learn about our commitment to creating possibilities for those living with serious disease.

    Patients & Families

  • Our Company
    • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors

    Meet Scholar Rock, a biopharmaceutical company committed to improving lives.

    Our Company

  • Our Science
    • Our Science
    • Platform
    • Publications & Posters

    Discover how our breakthrough approach treats complex disease at its biological root.

    Our Science

  • Our Pipeline
    • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
      • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Investors & Media
    • Investor Overview
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filinigs
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
Home Our Science Publications & Posters

Publications & Posters

Scholary publications

Spinal Muscular Atrophy

Apitegromab

June 2024

Cure SMA Annual Conference

An Update on Scholar Rock’s Progress in SMA

View this Poster

Immuno-Oncology

SRK-181

June 2024

American Society of Clinical Oncology

Phase1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in anti-PD1 resistant patients with advanced solid tumors: Updated results of expansion phase

View this Presentation

Spinal Muscular Atrophy

Apitegromab

March 2024

4th Scientific International Congress on SMA

Effect Of Apitegromab on Motor Function and Patient-reported Outcomes at 36 Months in Patients Aged 2-21 Years with Spinal Muscular Atrophy

View this Presentation

Spinal Muscular Atrophy

March 2024

2024 Muscular Dystrophy Association Clinical and Scientific Conference

Disease Burden in Patients with Spinal Muscular Atrophy (SMA) Treated with Survival Motor Neuron (SMN)-Targeted Therapies: A Targeted Literature Review

View this Poster

Spinal Muscular Atrophy

Apitegromab

March 2024

2024 Muscular Dystrophy Association Clinical and Scientific Conference

Effect of apitegromab on motor function and patient-reported outcomes at 36 months in patients aged 2-21 years with spinal muscular atrophy

View this Poster

Spinal Muscular Atrophy

Apitegromab

February 2024

Neurology

Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3

View this Publication

  • Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Interim pages omitted …
  • Page 14
  • Next

Footer

Scholar Rock, Inc.
301 Binney Street, 3rd Floor
Cambridge, MA 02142

Phone: 857.259.3860
[email protected]

LinkedIn X, formally Twitter
© 2025 All Rights Reserved
  • Community Guidelines
  • Expanded Access
  • Privacy Policy
  • Terms of Use

We are Scholar Rock.

A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.

Learn More About Our Pipeline

  • Community Guidelines
  • Expanded Access
  • Privacy Policy
  • Terms of Use
logo
  • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access
  • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors
    • Partnering
  • Our Science
    • Platform
    • Publications & Posters
  • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
      • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
  • Careers
  • Newsroom
  • Contact Us

You are now leaving the Scholar Rock website.

This external link is provided for your convenience. Scholar Rock is not responsible for content on external websites.

Continue